TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04869969

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous nephrolithotomy (supine position)
Description: percutaneous nephrolithotomy to be done in the supine position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous nephrolithotomy ( prone position)
Description: percutaneous nephrolithotomy in the prone position
Study: NCT00876759

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole brain radiotherapy
Description: WBRT in 10 fractions to a total dose of 30Gy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole brain radiotherapy with simultaneous boost
Description: Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
Study: NCT04435834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol or Sevoflurane
Description: Patient's will be randomized to the group receiving propofol, or the group receiving sevoflurane.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol or Sevoflurane
Description: Patient's will be randomized to the group receiving propofol, or the group receiving sevoflurane.
Study: NCT03676218

Intervention type: OTHER
Intervention: Elderly cancer patients
Description: No intervention: consensus of international experts to provide definition of survival endpoints to be used in randomized controlled trials to assess treatment efficacy.
Study: NCT02609087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Study: NCT02941224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SELUTION DCB (sirolimus coated balloon)
Study: NCT01112878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill
Description: Dosage form: capsule, by mouth~Dosage: not applicable~Frequency and Dosage:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill
Description: Dosage form: capsule, by mouth~Dosage: not applicable~Frequency and Dosage:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Dosage form: capsule, by mouth~Dosage: 600 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery.
Study: NCT02400645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-incisional wound infiltration
Description: Intraoperative: Pre-incisional bupivacaine 0.25% up to 20 cc divided dose for trocar incisions
Study: NCT02609087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Study: NCT01112878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: Dosage form: capsule, by mouth~Dosage: 600 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Dosage form: capsule, by mouth~Dosage: 0.2 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery.
Study: NCT02062749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
Study: NCT00435266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Remote ischemic preconditioning
Description: Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
Study: NCT00638248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmoteplase
Description: Desmoteplase 90µg/kg BW i.v. bolus
Study: NCT02400645

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscope to place TAP block with liposomal bupivacaine
Description: Intraoperative: Laparoscopic TAP block with Liposomal bupivacaine and bupivacaine 0.25%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Use of Liposomal bupivacaine in laparoscopic TAP block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.
Study: NCT00638248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmoteplase
Description: Desmoteplase 125 µg/kg BW i.v. bolus
Study: NCT01960660

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acids
Study: NCT01112878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clonidine
Description: Dosage form: capsule, by mouth~Dosage: 0.2 mg~Frequency and duration:~* once in the preoperative holding area and once before discharge from PACU~* continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery.
Study: NCT00638248

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo i.v. bolus
Study: NCT01960660

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acids

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 Fatty Acids
Study: NCT02616120

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SQJZ herbal mixtures
Description: The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
Study: NCT01960660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids
Study: NCT01147068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5mL Intramuscular Injection
Description: 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5mL Intramuscular Injection
Description: 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5mL Intramuscular Injection
Description: 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5mL Intramuscular Injection
Description: 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5mL Intramuscular Injection
Description: 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5mL Intramuscular Injection
Description: 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: 0.5mL Intramuscular Injection
Description: 0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle
Study: NCT00668317

Intervention type: DRUG
Group type: OTHER
Intervention: Omeprazole
Description: 20 mg BD tablet 8 weeks duration

Intervention type: DRUG
Group type: OTHER
Intervention: Ranitidine
Description: 300 mg od nocte tablet 8weeks duration
Study: NCT00954343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave
Study: NCT00672906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Parent Training
Description: Skills group for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maudsley Family Therapy
Description: Family therapy specifically adapted for the treatment of adolescent anorexia nervosa.
Study: NCT03831035

Intervention type: OTHER
Intervention: Genetic analyse by whole exome sequencing
Description: Exome sequencing requires analytic, bio informatic and interpretation steps.
Study: NCT03152591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching LIK066 tablets, for oral administration
Study: NCT04680481

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation
Description: Traveling wave transcranial alternating current stimulation will be applied at 4 Hz and 23 Hz over frontal and parietal brain areas in a randomized counterbalanced order.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial alternating current stimulation
Description: Traveling wave transcranial alternating current stimulation will be applied at 4 Hz and 23 Hz over frontal and parietal brain areas in a randomized counterbalanced order.
Study: NCT03992846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back capsule (E2 1 mg / NETA 0.5 mg)
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet to match 75 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet to match 75 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet to match 200 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet to match 200 mg linzagolix tablet
Description: For oral administration once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule to match Add-back capsule
Description: For oral administration once daily
Study: NCT01007227

Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle instruction
Description: Instruction dietetic and exercise therapy
Study: NCT00954343

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave
Study: NCT04657497

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified Dosage and Duration of Treatment
Study: NCT00082433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone + Capecitabine
Description: Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
Study: NCT02251600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Oral deflazacort administered once daily at 0.9 mg/kg for eight days
Study: NCT01669187

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education brochure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Live education and exercise instruction
Description: Participants will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
Study: NCT02392585

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single tourniquet
Description: Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Triple tourniquet
Description: Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.~Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary.
Study: NCT00082433

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
Study: NCT03198338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25% Bupivacaine, 0.5mL/kg
Description: Ultrasound guided TAP block using 0.25% Bupivacaine, 0.5ml/kg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: 0.9% Normal Saline

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound guided TAP block

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound guided TAP block
Study: NCT02358239

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Experiment group received acupuncture at Zusanli (ST36) and Neiguan (PC6) acupuncture points
Study: NCT01495000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: denosumab
Description: 60mg subcutaneous injection, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo subcutaneous injection, single dose
Study: NCT01268527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.03% E6201
Description: Topical 0.03% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.1% E6201
Description: Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% E6201
Description: Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.005% E6201
Description: Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% E6201
Description: Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% E6201
Description: Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo - 0.03% gel vehicle
Description: Topical 0.03% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo - 0.1% gel vehicle
Description: Topical 0.1% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo - 0.2% gel vehicle
Description: Topical 0.2% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo - 0.05% gel vehicle
Description: Topical 0.005% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo - 0.01% gel vehicle
Description: Topical 0.01% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo - 0.05% gel vehicle
Description: Topical 0.05% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
Study: NCT03992846

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule to match Add-back capsule
Description: For oral administration once daily
Study: NCT04578067

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: on physical activity and healthier eating
Study: NCT00854815

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Irrigation
Description: Irrigation of the area with at least 500ml NS using the power suction/irrigator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No Irrigation
Description: Suction only using suction/irrigator
Study: NCT01268527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene
Description: Topical 0.005% calcipotriene (positive control) was applied once daily to individual specific regions of the psoriatic plaque.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene
Description: Topical 0.005% calcipotriene (positive control) was applied once daily to individual specific regions of the psoriatic plaque.
Study: NCT02224989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging
Description: An awareness training program. One 2 hr class per week for 10 weeks.
Study: NCT01257945

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexibility and Function exercise program
Study: NCT03409588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adempas
Description: After obtaining baseline data, patients will be placed on oral riociguat at a dose of 0.5 mg TID which will be up titrated over two months to a maximum dose of 2.5 mg TID or maximum tolerated dose. After 3 months from onset of riociguat initiation, the University of California San Diego (UCSD) shortness of breath score, 6 Minute Walk Test (6MWD), and resting/exercise Right Heart Catheterization (RHC) will be repeated.
Study: NCT00477048

Intervention type: DRUG
Group type: OTHER
Intervention: Saquinavir
Description: SQV/r 1000/100 BID + NNRTI or SQV/r 1600/100 OD + 2 NRTI
Study: NCT03038386

Intervention type: OTHER
Group type: OTHER
Intervention: Dual Energy CT
Description: In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
Study: NCT02710721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Patients realize a 60h-modified fasting (36h before and 24h after chemotherapy) with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al. Between chemotherapy a Mediterranean diet with nutrition training individually and in small groups by trained nutritionists at the Study Centre will be practiced.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants of the control group will receive an individual nutrition training and in small groups according to the Mediterranean diet.
Study: NCT01526057

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280586
Description: 1000 mg, IV on days 1 and 15
Study: NCT01257945

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home exercise program
Study: NCT01526057

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: 1000 mg, IV on days 1 and 15

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan
Description: 1000 mg, IV on days 1 and 15
Study: NCT01414673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG
Description: 5000 IU

Intervention type: DRUG
Group type: OTHER
Intervention: HCG
Description: 5000 IU